Montauk Renewables heads into its May 7 earnings call having just printed a Q1 beat — and with short sellers in full retreat.
The earnings story is the standout this week. Q1 revenue came in at $46.4M, ahead of the $43.2M consensus estimate. The result dropped just hours before the scheduled conference call. It caps a month in which the stock has risen 35% to close at $1.54 — a powerful recovery from what had been a deeply depressed setup. The price gain follows the short interest unwind: ORTEX daily estimates show short interest collapsed from roughly 2.5 million shares on loan in early April to just 243,000 by May 5. That is a 90% month-on-month decline in shares short. SI has fallen to just 0.17% of free float — well below the level where short positioning is a meaningful story in either direction.
The lending market reflects that unwind. Borrow costs remain low at around 1.2%, barely changed on the week. The ORTEX short score has dropped from 45 in late April to 36 now — a move that confirms the short-seller retreat is real and not just noise. Availability is well supplied. There is no squeeze dynamic here; shorts have already left. The question for the rest of the week is what fundamental buyers do with the beat.
Analyst sentiment is uniformly neutral, and the targets have been moving the wrong way for over a year. UBS trimmed its price target to $1.60 from $2.85 just two weeks ago, maintaining Neutral. Scotiabank cut to $2.00 from $4.00 at the same time. The consensus of four analysts all sitting on Hold ratings tells a story of a Street that acknowledges the business but sees limited near-term re-rating catalysts. The mean target of $1.775 is modestly above the current price, but that margin is thin given how aggressively targets have been reduced across the coverage universe. The EV/EBITDA multiple has expanded to 5.3x on the back of the price recovery — still modest, and the P/B at 0.76 suggests the market values the asset base at a discount to book. EPS momentum is the one genuine bright spot in factor scores: the 30-day and 90-day momentum ranks sit at the 92nd and 88th percentiles respectively, and the 12-month forward EPS growth estimate scores in the 95th percentile.
Ownership is concentrated in a way that matters. Three holders — John Copelyn, Aktiv Investment Management, and Theventheran Govender — together control roughly 68% of shares. That concentration has not shifted in the latest filings. BlackRock and Vanguard hold small positions and added modestly in Q1. The only notable insider change is CEO Sean McClain, whose holdings fell by 313,455 shares in the most recent filing. Insider trade data is stale beyond six months and the recent sell follows a pattern of small annual disposals from a VP — nothing that reads as a directional signal.
The options market offers almost no signal. The put/call ratio has been at zero for most of the past three weeks, with virtually no put volume in the market. That near-zero reading is consistent with the very low short interest — there is little hedging activity, and call interest dominates the thin options flow.
The May 7 earnings call is the immediate focal point — the market has the revenue beat in hand, and what analysts and investors are now listening for is management's commentary on volumes, renewable natural gas pricing, and any project pipeline updates that could frame the rest of 2026.
See the live data behind this article on ORTEX.
Open MNTK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
